{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:09:21Z","timestamp":1791864561059,"version":"4.3.4"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"BMBF - DKTK","award":["ED03"],"award-info":[{"award-number":["ED03"]}]},{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40257-024-00858-z","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T19:01:31Z","timestamp":1713812491000},"page":"541-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-653X","authenticated-orcid":false,"given":"J\u00fcrgen C.","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6363-9061","authenticated-orcid":false,"given":"Andreas","family":"Stang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6931-8194","authenticated-orcid":false,"given":"David","family":"Schrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9384-6704","authenticated-orcid":false,"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"858_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2018.02.003","volume":"94","author":"A Stang","year":"2018","unstructured":"Stang A, Becker JC, Nghiem P, Ferlay J. The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: an international assessment. Eur J Cancer. 2018;94:47\u201360.","journal-title":"Eur J Cancer"},{"issue":"1","key":"858_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamadermatol.2020.4102","volume":"157","author":"D Jacobs","year":"2021","unstructured":"Jacobs D, Huang H, Olino K, Weiss S, Kluger H, Judson BL, Zhang Y. Assessment of age, period, and birth cohort effects and trends in Merkel cell carcinoma incidence in the United States. JAMA Dermatol. 2021;157(1):59\u201365.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"858_CR3","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.jaad.2018.08.021","volume":"80","author":"KG Paulson","year":"2019","unstructured":"Paulson KG, Nghiem P. One in a hundred million: Merkel cell carcinoma in pediatric and young adult patients is rare but more likely to present at advanced stages based on US registry data. J Am Acad Dermatol. 2019;80(6):1758\u201360.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"858_CR4","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0190-9622(03)02108-X","volume":"49","author":"M Agelli","year":"2003","unstructured":"Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003;49(5):832\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"858_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ejca.2011.06.001","volume":"48","author":"H Kukko","year":"2012","unstructured":"Kukko H, Bohling T, Koljonen V, Tukiainen E, Haglund C, Pokhrel A, et al. Merkel cell carcinoma\u2014a population-based epidemiological study in Finland with a clinical series of 181 cases. Eur J Cancer. 2012;48(5):737\u201342.","journal-title":"Eur J Cancer"},{"issue":"2","key":"858_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/bjd\/ljac044","volume":"188","author":"K Mistry","year":"2023","unstructured":"Mistry K, Levell NJ, Hollestein L, Wakkee M, Nijsten T, Knott CS, et al. Trends in incidence, treatment and survival of Merkel cell carcinoma in England 2004\u20132018: a cohort study. Br J Dermatol. 2023;188(2):228\u201336.","journal-title":"Br J Dermatol"},{"issue":"8","key":"858_CR7","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamadermatol.2014.124","volume":"150","author":"DR Youlden","year":"2014","unstructured":"Youlden DR, Soyer HP, Youl PH, Fritschi L, Baade PD. Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993\u20132010. JAMA Dermatol. 2014;150(8):864\u201372.","journal-title":"JAMA Dermatol"},{"issue":"9305","key":"858_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(02)07668-7","volume":"359","author":"EA Engels","year":"2002","unstructured":"Engels EA, Frisch M, Goedert JJ, Biggar RJ, Miller RW. Merkel cell carcinoma and HIV infection. Lancet. 2002;359(9305):497\u20138.","journal-title":"Lancet"},{"issue":"4","key":"858_CR9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jid.2022.09.008","volume":"143","author":"YT Luu","year":"2023","unstructured":"Luu YT, Luo Q, Horner MJ, Shiels M, Engels EA, Sargen MR. Risk of Nonkeratinocyte skin cancers in people living with HIV during the era of antiretroviral therapy. J Investig Dermatol. 2023;143(4):588\u201395 (e3).","journal-title":"J Investig Dermatol"},{"issue":"2","key":"858_CR10","doi-asserted-by":"publisher","first-page":"dju382","DOI":"10.1093\/jnci\/dju382","volume":"107","author":"CA Clarke","year":"2015","unstructured":"Clarke CA, Robbins HA, Tatalovich Z, Lynch CF, Pawlish KS, Finch JL, et al. Risk of Merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst. 2015;107(2):dju382.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"858_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","volume":"78","author":"SA Pedersen","year":"2018","unstructured":"Pedersen SA, Gaist D, Schmidt SAJ, Holmich LR, Friis S, Pottegard A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673\u201381 (e9).","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"858_CR12","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/bjd.18218","volume":"181","author":"E Keeling","year":"2019","unstructured":"Keeling E, Murray SL, Williams Y, Sexton DJ, O\u2019Kelly P, Deady S, et al. Merkel cell carcinoma in kidney transplant recipients in Ireland 1964\u20132018. Br J Dermatol. 2019;181(6):1314\u20135.","journal-title":"Br J Dermatol"},{"issue":"11","key":"858_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1001\/jamadermatol.2023.2849","volume":"159","author":"E Eid","year":"2023","unstructured":"Eid E, Maloney NJ, Cai ZR, Zaba LC, Kibbi N, John EM, Linos E. Risk of multiple primary cancers in patients with Merkel cell carcinoma: a SEER-based analysis. JAMA Dermatol. 2023;159(11):1248\u201352.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"858_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/bjd.14352","volume":"174","author":"N Eisemann","year":"2016","unstructured":"Eisemann N, Jansen L, Castro FA, Chen T, Eberle A, Nennecke A, et al. Survival with nonmelanoma skin cancer in Germany. Br J Dermatol. 2016;174(4):778\u201385.","journal-title":"Br J Dermatol"},{"key":"858_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jaad.2023.11.020","volume":"90","author":"AM McEvoy","year":"2023","unstructured":"McEvoy AM, Hippe DS, Lachance K, Park S, Cahill K, Redman M, et al. Merkel cell carcinoma recurrence risk estimation is improved by integrating factors beyond cancer stage: a multivariable model and web-based calculator. J Am Acad Dermatol. 2023;90:569\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"858_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamadermatol.2021.6096","volume":"158","author":"AM McEvoy","year":"2022","unstructured":"McEvoy AM, Lachance K, Hippe DS, Cahill K, Moshiri Y, Lewis CW, et al. Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis. JAMA Dermatol. 2022;158(4):382\u20139.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"858_CR17","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","volume":"4","author":"M Plummer","year":"2016","unstructured":"Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609\u201316.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"858_CR18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3390\/ijms19040970","volume":"19","author":"AK Basu","year":"2018","unstructured":"Basu AK. DNA damage, mutagenesis and cancer. Int J Mol Sci. 2018;19(4):970.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"858_CR19","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1158\/0008-5472.CAN-11-0342","volume":"71","author":"J DeGregori","year":"2011","unstructured":"DeGregori J. Evolved tumor suppression: why are we so good at not getting cancer? Cancer Res. 2011;71(11):3739\u201344.","journal-title":"Cancer Res"},{"issue":"18","key":"858_CR20","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1002\/1878-0261.13275","volume":"16","author":"F Marongiu","year":"2022","unstructured":"Marongiu F, DeGregori J. The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging-related disease. Mol Oncol. 2022;16(18):3238\u201358.","journal-title":"Mol Oncol"},{"issue":"3","key":"858_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41590-022-01127-z","volume":"23","author":"N Jacquelot","year":"2022","unstructured":"Jacquelot N, Seillet C, Vivier E, Belz GT. Innate lymphoid cells and cancer. Nat Immunol. 2022;23(3):371\u20139.","journal-title":"Nat Immunol"},{"key":"858_CR22","doi-asserted-by":"publisher","first-page":"4684268","DOI":"10.1155\/2016\/4684268","volume":"2016","author":"C Cantoni","year":"2016","unstructured":"Cantoni C, Huergo-Zapico L, Parodi M, Pedrazzi M, Mingari MC, Moretta A, et al. NK cells, tumor cell transition, and tumor progression in solid malignancies: new hints for NK-based immunotherapy? J Immunol Res. 2016;2016:4684268.","journal-title":"J Immunol Res"},{"issue":"5","key":"858_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1158\/2326-6066.CIR-22-0148","volume":"10","author":"D Kabelitz","year":"2022","unstructured":"Kabelitz D. A menage a trois of cytotoxic effector cells: gammadelta T cells suppress NK cells but not CTLs. Cancer Immunol Res. 2022;10(5):543.","journal-title":"Cancer Immunol Res"},{"key":"858_CR24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190457","author":"V Koliaraki","year":"2020","unstructured":"Koliaraki V, Henriques A, Prados A, Kollias G. Unfolding innate mechanisms in the cancer microenvironment: the emerging role of the mesenchyme. J Exp Med. 2020. https:\/\/doi.org\/10.1084\/jem.20190457.","journal-title":"J Exp Med"},{"key":"858_CR25","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3389\/fimmu.2019.01014","volume":"10","author":"R Noubade","year":"2019","unstructured":"Noubade R, Majri-Morrison S, Tarbell KV. Beyond cDC1: Emerging roles of DC crosstalk in cancer immunity. Front Immunol. 2019;10:1014.","journal-title":"Front Immunol"},{"issue":"1","key":"858_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/imr.13281","volume":"321","author":"C Luri-Rey","year":"2024","unstructured":"Luri-Rey C, Gomis G, Glez-Vaz J, Manzanal A, Martinez Riano A, Rodriguez Ruiz ME, et al. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming. Immunol Rev. 2024;321(1):143\u201351.","journal-title":"Immunol Rev"},{"key":"858_CR27","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3389\/fimmu.2020.00624","volume":"11","author":"ND Bhattacharyya","year":"2020","unstructured":"Bhattacharyya ND, Feng CG. Regulation of T helper cell fate by TCR signal strength. Front Immunol. 2020;11:624.","journal-title":"Front Immunol"},{"issue":"9","key":"858_CR28","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.3390\/cancers12092607","volume":"12","author":"A Apavaloaei","year":"2020","unstructured":"Apavaloaei A, Hardy MP, Thibault P, Perreault C. The origin and immune recognition of tumor-specific antigens. Cancers (Basel). 2020;12(9):2607.","journal-title":"Cancers (Basel)"},{"key":"858_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2017.12.009","volume":"84","author":"C Macri","year":"2018","unstructured":"Macri C, Pang ES, Patton T, O\u2019Keeffe M. Dendritic cell subsets. Semin Cell Dev Biol. 2018;84:11\u201321.","journal-title":"Semin Cell Dev Biol"},{"key":"858_CR30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3389\/fimmu.2015.00563","volume":"6","author":"R Obst","year":"2015","unstructured":"Obst R. The timing of T cell priming and cycling. Front Immunol. 2015;6:563.","journal-title":"Front Immunol"},{"issue":"6576","key":"858_CR31","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375(6576):eabf9419.","journal-title":"Science"},{"issue":"6","key":"858_CR32","doi-asserted-by":"publisher","first-page":"e002273","DOI":"10.1136\/jitc-2020-002273","volume":"9","author":"KT Lynch","year":"2021","unstructured":"Lynch KT, Young SJ, Meneveau MO, Wages NA, Engelhard VH, Slingluff CL Jr, Mauldin IS. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. J Immunother Cancer. 2021;9(6):e002273.","journal-title":"J Immunother Cancer"},{"key":"858_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.811586","volume":"12","author":"M Nakamura","year":"2022","unstructured":"Nakamura M, Magara T, Kano S, Matsubara A, Kato H, Morita A. Tertiary lymphoid structures and chemokine landscape in virus-positive and virus-negative Merkel cell carcinoma. Front Oncol. 2022;12: 811586.","journal-title":"Front Oncol"},{"issue":"1","key":"858_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12105","volume":"1284","author":"MD Vesely","year":"2013","unstructured":"Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci. 2013;1284(1):1\u20135.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"858_CR35","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther. 2023;8(1):200.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"858_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2017.10.028","volume":"78","author":"KG Paulson","year":"2018","unstructured":"Paulson KG, Park SY, Vandeven NA, Lachance K, Thomas H, Chapuis AG, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457\u201363 (e2).","journal-title":"J Am Acad Dermatol"},{"key":"858_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijscr.2014.11.027","volume":"7C","author":"C Pang","year":"2015","unstructured":"Pang C, Sharma D, Sankar T. Spontaneous regression of Merkel cell carcinoma: a case report and review of the literature. Int J Surg Case Rep. 2015;7C:104\u20138.","journal-title":"Int J Surg Case Rep"},{"issue":"7","key":"858_CR38","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/1346-8138.14335","volume":"45","author":"K Nagase","year":"2018","unstructured":"Nagase K, Inoue T, Koba S, Narisawa Y. Case of probable spontaneous regression of Merkel cell carcinoma combined with squamous cell carcinoma without surgical intervention. J Dermatol. 2018;45(7):858\u201361.","journal-title":"J Dermatol"},{"issue":"24","key":"858_CR39","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1158\/0008-5472.CAN-15-1877","volume":"75","author":"SQ Wong","year":"2015","unstructured":"Wong SQ, Waldeck K, Vergara IA, Schroder J, Madore J, Wilmott JS, et al. UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. Cancer Res. 2015;75(24):5228\u201334.","journal-title":"Cancer Res"},{"issue":"1","key":"858_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jid.2016.08.015","volume":"137","author":"MDC Gonzalez-Vela","year":"2017","unstructured":"Gonzalez-Vela MDC, Curiel-Olmo S, Derdak S, Beltran S, Santibanez M, Martinez N, et al. Shared oncogenic pathways implicated in both virus-positive and UV-induced Merkel cell carcinomas. J Investig Dermatol. 2017;137(1):197\u2013206.","journal-title":"J Investig Dermatol"},{"issue":"9","key":"858_CR41","doi-asserted-by":"publisher","first-page":"e005328","DOI":"10.1136\/jitc-2022-005328","volume":"10","author":"C Church","year":"2022","unstructured":"Church C, Pulliam T, Longino N, Park SY, Smythe KS, Makarov V, et al. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma. J Immunother Cancer. 2022;10(9):e005328.","journal-title":"J Immunother Cancer"},{"issue":"5866","key":"858_CR42","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1126\/science.1152586","volume":"319","author":"H Feng","year":"2008","unstructured":"Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096\u2013100.","journal-title":"Science"},{"key":"858_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.868781","volume":"12","author":"WA Wijaya","year":"2022","unstructured":"Wijaya WA, Liu Y, Qing Y, Li Z. Prevalence of Merkel cell polyomavirus in normal and lesional skin: a systematic review and meta-analysis. Front Oncol. 2022;12: 868781.","journal-title":"Front Oncol"},{"issue":"9","key":"858_CR44","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1172\/JCI46323","volume":"121","author":"M Shuda","year":"2011","unstructured":"Shuda M, Kwun HJ, Feng H, Chang Y, Moore PS. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Investig. 2011;121(9):3623\u201334.","journal-title":"J Clin Investig"},{"issue":"14","key":"858_CR45","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.1128\/JVI.02400-09","volume":"84","author":"R Houben","year":"2010","unstructured":"Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol. 2010;84(14):7064\u201372.","journal-title":"J Virol"},{"issue":"8","key":"858_CR46","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1073\/pnas.1815239116","volume":"116","author":"NP Croft","year":"2019","unstructured":"Croft NP, Smith SA, Pickering J, Sidney J, Peters B, Faridi P, et al. Most viral peptides displayed by class I MHC on infected cells are immunogenic. Proc Natl Acad Sci USA. 2019;116(8):3112\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"858_CR47","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1158\/1078-0432.CCR-13-2697","volume":"20","author":"R Lyngaa","year":"2014","unstructured":"Lyngaa R, Pedersen NW, Schrama D, Thrue CA, Ibrani D, Met O, et al. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish patients with Merkel cell carcinoma from healthy donors. Clin Cancer Res. 2014;20(7):1768\u201378.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"858_CR48","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2326-6066.CIR-19-0647","volume":"8","author":"L Jing","year":"2020","unstructured":"Jing L, Ott M, Church CD, Kulikauskas RM, Ibrani D, Iyer JG, et al. Prevalent and diverse intratumoral oncoprotein-specific CD8(+) T cells within polyomavirus-driven Merkel cell carcinomas. Cancer Immunol Res. 2020;8(5):648\u201359.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"858_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jid.2021.06.027","volume":"142","author":"UK Hansen","year":"2022","unstructured":"Hansen UK, Lyngaa R, Ibrani D, Church C, Verhaegen M, Dlugosz AA, et al. Extended T-cell epitope landscape in Merkel cell polyomavirus large T and small T oncoproteins identified uniquely in patients with cancer. J Investig Dermatol. 2022;142(1):239\u201343 (e13).","journal-title":"J Investig Dermatol"},{"key":"858_CR50","doi-asserted-by":"publisher","first-page":"1172913","DOI":"10.3389\/fimmu.2023.1172913","volume":"14","author":"S Jani","year":"2023","unstructured":"Jani S, Church CD, Nghiem P. Insights into anti-tumor immunity via the polyomavirus shared across human Merkel cell carcinomas. Front Immunol. 2023;14:1172913.","journal-title":"Front Immunol"},{"issue":"2","key":"858_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2326-6066.CIR-16-0210","volume":"5","author":"NJ Miller","year":"2017","unstructured":"Miller NJ, Church CD, Dong L, Crispin D, Fitzgibbon MP, Lachance K, et al. Tumor-infiltrating Merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival. Cancer Immunol Res. 2017;5(2):137\u201347.","journal-title":"Cancer Immunol Res"},{"issue":"19","key":"858_CR52","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1158\/1078-0432.CCR-13-0035","volume":"19","author":"OK Afanasiev","year":"2013","unstructured":"Afanasiev OK, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer JG, et al. Merkel polyomavirus-specific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res. 2013;19(19):5351\u201360.","journal-title":"Clin Cancer Res"},{"key":"858_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2019.103961","volume":"344","author":"M Samimi","year":"2019","unstructured":"Samimi M, Benlalam H, Aumond P, Gaboriaud P, Fradin D, Kervarrec T, et al. Viral and tumor antigen-specific CD8 T-cell responses in Merkel cell carcinoma. Cell Immunol. 2019;344: 103961.","journal-title":"Cell Immunol"},{"issue":"12","key":"858_CR54","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2010.30.6308","volume":"29","author":"KG Paulson","year":"2011","unstructured":"Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, et al. Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol. 2011;29(12):1539\u201346.","journal-title":"J Clin Oncol"},{"issue":"4","key":"858_CR55","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1309\/AJCPIKDZM39CRPNC","volume":"142","author":"KG Paulson","year":"2014","unstructured":"Paulson KG, Iyer JG, Simonson WT, Blom A, Thibodeau RM, Schmidt M, et al. CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. Am J Clin Pathol. 2014;142(4):452\u20138.","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"858_CR56","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"858_CR57","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"Kallies A, Zehn D, Utzschneider DT. Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol. 2020;20(2):128\u201336.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"858_CR58","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326\u201336.","journal-title":"Nat Immunol"},{"key":"858_CR59","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.canlet.2021.02.013","volume":"506","author":"H Cheng","year":"2021","unstructured":"Cheng H, Ma K, Zhang L, Li G. The tumor microenvironment shapes the molecular characteristics of exhausted CD8(+) T cells. Cancer Lett. 2021;506:55\u201366.","journal-title":"Cancer Lett"},{"key":"858_CR60","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.3389\/fimmu.2018.03059","volume":"9","author":"C Fu","year":"2018","unstructured":"Fu C, Jiang A. Dendritic cells and CD8 T cell immunity in tumor microenvironment. Front Immunol. 2018;9:3059.","journal-title":"Front Immunol"},{"issue":"7","key":"858_CR61","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/jid.2013.75","volume":"133","author":"M Dowlatshahi","year":"2013","unstructured":"Dowlatshahi M, Huang V, Gehad AE, Jiang Y, Calarese A, Teague JE, et al. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Investig Dermatol. 2013;133(7):1879\u201389.","journal-title":"J Investig Dermatol"},{"issue":"3","key":"858_CR62","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173\u201385.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"858_CR63","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1038\/s41598-017-02608-0","volume":"7","author":"C Ritter","year":"2017","unstructured":"Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, et al. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci Rep. 2017;7(1):2290.","journal-title":"Sci Rep"},{"key":"858_CR64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151666","author":"PC Lee","year":"2022","unstructured":"Lee PC, Klaeger S, Le PM, Korthauer K, Cheng J, Ananthapadmanabhan V, et al. Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. J Clin Investig. 2022. https:\/\/doi.org\/10.1172\/JCI151666.","journal-title":"J Clin Investig"},{"key":"858_CR65","doi-asserted-by":"publisher","first-page":"21678","DOI":"10.1038\/srep21678","volume":"6","author":"C Ritter","year":"2016","unstructured":"Ritter C, Fan K, Paulson KG, Nghiem P, Schrama D, Becker JC. Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. Sci Rep. 2016;6:21678.","journal-title":"Sci Rep"},{"issue":"11","key":"858_CR66","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1158\/2326-6066.CIR-14-0005","volume":"2","author":"KG Paulson","year":"2014","unstructured":"Paulson KG, Tegeder A, Willmes C, Iyer JG, Afanasiev OK, Schrama D, et al. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. Cancer Immunol Res. 2014;2(11):1071\u20139.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"858_CR67","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/cancers6021047","volume":"6","author":"R Wheat","year":"2014","unstructured":"Wheat R, Roberts C, Waterboer T, Steele J, Marsden J, Steven NM, Blackbourn DJ. Inflammatory cell distribution in primary Merkel cell carcinoma. Cancers (Basel). 2014;6(2):1047\u201364.","journal-title":"Cancers (Basel)."},{"issue":"8","key":"858_CR68","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/jid.2013.36","volume":"133","author":"OK Afanasiev","year":"2013","unstructured":"Afanasiev OK, Nagase K, Simonson W, Vandeven N, Blom A, Koelle DM, et al. Vascular E-selectin expression correlates with CD8 lymphocyte infiltration and improved outcome in Merkel cell carcinoma. J Investig Dermatol. 2013;133(8):2065\u201373.","journal-title":"J Investig Dermatol"},{"issue":"10","key":"858_CR69","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17(10):1142\u20139.","journal-title":"Nat Immunol"},{"issue":"24","key":"858_CR70","doi-asserted-by":"publisher","first-page":"13730","DOI":"10.1073\/pnas.1919690117","volume":"117","author":"W Liu","year":"2020","unstructured":"Liu W, Kim GB, Krump NA, Zhou Y, Riley JL, You J. Selective reactivation of STING signaling to target Merkel cell carcinoma. Proc Natl Acad Sci USA. 2020;117(24):13730\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"858_CR71","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1016\/j.jid.2022.08.019","volume":"142","author":"TH Pulliam","year":"2022","unstructured":"Pulliam TH, Bhakuni R, Jani S, Smythe K, Seaton B, Tachiki L, et al. An intratumoral STING agonist-mediated clinical response in PD-L1-refractory MCC via an unexpected mechanism of action. J Investig Dermatol. 2022;142(10):2839.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"858_CR72","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2326-6066.CIR-13-0034","volume":"1","author":"EJ Lipson","year":"2013","unstructured":"Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54\u201363.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"858_CR73","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12022-019-09601-5","volume":"31","author":"C Ricci","year":"2020","unstructured":"Ricci C, Righi A, Ambrosi F, Gibertoni D, Maletta F, Uccella S, et al. Prognostic impact of MCPyV and TIL subtyping in Merkel cell carcinoma: evidence from a large European cohort of 95 patients. Endocr Pathol. 2020;31(1):21\u201332.","journal-title":"Endocr Pathol"},{"issue":"9","key":"858_CR74","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-19-2244","volume":"26","author":"I Spassova","year":"2020","unstructured":"Spassova I, Ugurel S, Terheyden P, Sucker A, Hassel JC, Ritter C, et al. Predominance of central memory T cells with high T-cell receptor repertoire diversity is associated with response to PD-1\/PD-L1 inhibition in Merkel cell carcinoma. Clin Cancer Res. 2020;26(9):2257\u201367.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"858_CR75","doi-asserted-by":"publisher","first-page":"e003198","DOI":"10.1136\/jitc-2021-003198","volume":"10","author":"I Spassova","year":"2022","unstructured":"Spassova I, Ugurel S, Kubat L, Zimmer L, Terheyden P, Mohr A, et al. Clinical and molecular characteristics associated with response to therapeutic PD-1\/PD-L1 inhibition in advanced Merkel cell carcinoma. J Immunother Cancer. 2022;10(1):e003198.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"858_CR76","doi-asserted-by":"publisher","first-page":"e001631","DOI":"10.1136\/jitc-2020-001631","volume":"8","author":"S Simon","year":"2020","unstructured":"Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, et al. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. J Immunother Cancer. 2020;8(2):e001631.","journal-title":"J Immunother Cancer"},{"issue":"7620","key":"858_CR77","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417\u201321.","journal-title":"Nature"},{"issue":"8","key":"858_CR78","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25(8):1251\u20139.","journal-title":"Nat Med"},{"issue":"7798","key":"858_CR79","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJ, Chitre AS, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. 2020;579(7798):274\u20138.","journal-title":"Nature"},{"issue":"1","key":"858_CR80","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu B, Hu X, Feng K, Gao R, Xue Z, Zhang S, et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat Cancer. 2022;3(1):108\u201321.","journal-title":"Nat Cancer."},{"issue":"7","key":"858_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100127","volume":"1","author":"S Corgnac","year":"2020","unstructured":"Corgnac S, Malenica I, Mezquita L, Auclin E, Voilin E, Kacher J, et al. CD103(+)CD8(+) T(RM) cells accumulate in tumors of anti-PD-1-responder lung cancer patients and are tumor-reactive lymphocytes enriched with Tc17. Cell Rep Med. 2020;1(7): 100127.","journal-title":"Cell Rep Med."},{"issue":"16","key":"858_CR82","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","volume":"185","author":"AM Luoma","year":"2022","unstructured":"Luoma AM, Suo S, Wang Y, Gunasti L, Porter CBM, Nabilsi N, et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell. 2022;185(16):2918\u201335 (e29).","journal-title":"Cell"},{"issue":"6","key":"858_CR83","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","volume":"186","author":"MK Rahim","year":"2023","unstructured":"Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, et al. Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell. 2023;186(6):1127\u201343 (e18).","journal-title":"Cell"},{"issue":"7791","key":"858_CR84","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561\u20135.","journal-title":"Nature"},{"issue":"8","key":"858_CR85","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853\u201360.","journal-title":"Ann Oncol"},{"issue":"12","key":"858_CR86","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26(12):1839\u201344.","journal-title":"Nat Med"},{"issue":"1","key":"858_CR87","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/s41467-018-06300-3","volume":"9","author":"KG Paulson","year":"2018","unstructured":"Paulson KG, Voillet V, McAfee MS, Hunter DS, Wagener FD, Perdicchio M, et al. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun. 2018;9(1):3868.","journal-title":"Nat Commun"},{"issue":"6","key":"858_CR88","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00262-019-02341-9","volume":"68","author":"S Ugurel","year":"2019","unstructured":"Ugurel S, Spassova I, Wohlfarth J, Drusio C, Cherouny A, Melior A, et al. MHC class-I downregulation in PD-1\/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series. Cancer Immunol Immunother. 2019;68(6):983\u201390.","journal-title":"Cancer Immunol Immunother"},{"key":"858_CR89","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1158\/1078-0432.CCR-23-1957","volume":"30","author":"S Tabachnick-Cherny","year":"2023","unstructured":"Tabachnick-Cherny S, Pulliam T, Rodriguez HJ, Fan X, Hippe DS, Jones DC, et al. Characterization of immunosuppressive myeloid cells in Merkel cell carcinoma: correlation with resistance to PD-1 pathway blockade. Clin Cancer Res. 2023;30:1189\u201399.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"858_CR90","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017;7(3):264\u201376.","journal-title":"Cancer Discov"},{"issue":"7614","key":"858_CR91","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature18945","volume":"536","author":"EM Verdegaal","year":"2016","unstructured":"Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature. 2016;536(7614):91\u20135.","journal-title":"Nature"},{"issue":"9","key":"858_CR92","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"858_CR93","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","volume":"7","author":"DS Shin","year":"2017","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7(2):188\u2013201.","journal-title":"Cancer Discov"},{"issue":"3","key":"858_CR94","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/geriatrics3030034","volume":"3","author":"S Whelehan","year":"2018","unstructured":"Whelehan S, Lynch O, Treacy N, Gleeson C, Oates A, O\u2019Donovan A. Optimising clinical trial design in older cancer patients. Geriatrics (Basel). 2018;3(3):34.","journal-title":"Geriatrics (Basel)"},{"issue":"7","key":"858_CR95","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1001\/jamaoncol.2016.5296","volume":"3","author":"S Mailankody","year":"2017","unstructured":"Mailankody S, Prasad V. Overall survival in cancer drug trials as a new surrogate end point for overall survival in the real world. JAMA Oncol. 2017;3(7):889\u201390.","journal-title":"JAMA Oncol"},{"issue":"9","key":"858_CR96","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JCO.18.01896","volume":"37","author":"P Nghiem","year":"2019","unstructured":"Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol. 2019;37(9):693\u2013702.","journal-title":"J Clin Oncol"},{"issue":"10","key":"858_CR97","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D\u2019Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol"},{"issue":"9","key":"858_CR98","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0077","volume":"4","author":"SP D'Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Russell J, Lebbe C, Chmielowski B, Gambichler T, Grob JJ, et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. 2018;4(9): e180077.","journal-title":"JAMA Oncol"},{"issue":"8","key":"858_CR99","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40265-023-01884-7","volume":"83","author":"C Kang","year":"2023","unstructured":"Kang C. Retifanlimab: first approval. Drugs. 2023;83(8):731\u20137.","journal-title":"Drugs"},{"issue":"1","key":"858_CR100","doi-asserted-by":"publisher","first-page":"2297450","DOI":"10.1080\/19420862.2023.2297450","volume":"16","author":"S Crescioli","year":"2024","unstructured":"Crescioli S, Kaplon H, Chenoweth A, Wang L, Visweswaraiah J, Reichert JM. Antibodies to watch in 2024. MAbs. 2024;16(1):2297450.","journal-title":"MAbs"},{"key":"858_CR101","doi-asserted-by":"publisher","first-page":"S686","DOI":"10.1016\/j.annonc.2023.09.2280","volume":"34","author":"G Grignani","year":"2023","unstructured":"Grignani G, Rutkowski P, Lebbe C, Guida M, Gaudy Marqueste C, De Braud FGM, et al. Updated results from POD1UM-201: a phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma. Ann Oncol. 2023;34:S686.","journal-title":"Ann Oncol"},{"issue":"2","key":"858_CR102","doi-asserted-by":"publisher","first-page":"e001076","DOI":"10.1136\/jitc-2020-001076","volume":"8","author":"S Levy","year":"2020","unstructured":"Levy S, Aarts MJB, Eskens F, Keymeulen K, Been LB, Grunhagen D, et al. Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort. J Immunother Cancer. 2020;8(2):e001076.","journal-title":"J Immunother Cancer"},{"key":"858_CR103","first-page":"149","volume":"14","author":"R Lohray","year":"2023","unstructured":"Lohray R, Verma KK, Wang LL, Haynes D, Lewis DJ. Avelumab for advanced Merkel cell carcinoma: global real-world data on patient response and survival. Pragmat Obs Res. 2023;14:149\u201354.","journal-title":"Pragmat Obs Res."},{"issue":"14","key":"858_CR104","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.7150\/jca.57413","volume":"12","author":"L Al-Showbaki","year":"2021","unstructured":"Al-Showbaki L, Nadler MB, Desnoyers A, Almugbel FA, Cescon DW, Amir E. Network Meta-analysis comparing efficacy, safety and tolerability of anti-PD-1\/PD-L1 antibodies in solid cancers. J Cancer. 2021;12(14):4372\u20138.","journal-title":"J Cancer"},{"issue":"11","key":"858_CR105","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1007\/s00262-023-03539-8","volume":"72","author":"LML Tachiki","year":"2023","unstructured":"Tachiki LML, Hippe DS, Williams Silva K, Hall ET, McCamy W, Fritzsche D, et al. Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma. Cancer Immunol Immunother. 2023;72(11):3839\u201350.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"858_CR106","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/cncr.35050","volume":"130","author":"LP Zijlker","year":"2024","unstructured":"Zijlker LP, Levy S, Wolters W, van Thienen JV, van Akkooi ACJ, Tesselaar MET. Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET\/CT-confirmed complete response. Cancer. 2024;130(3):433\u20138.","journal-title":"Cancer"},{"issue":"26","key":"858_CR107","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542\u201352.","journal-title":"N Engl J Med"},{"issue":"7","key":"858_CR108","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/CJI.0000000000000432","volume":"45","author":"SZ Shalhout","year":"2022","unstructured":"Shalhout SZ, Emerick KS, Kaufman HL, Silk AW, Thakuria M, Miller DM. A Retrospective study of ipilimumab plus nivolumab in anti-PD-L1\/PD-1 refractory Merkel cell carcinoma. J Immunother. 2022;45(7):299\u2013302.","journal-title":"J Immunother"},{"issue":"11","key":"858_CR109","doi-asserted-by":"publisher","first-page":"e005930","DOI":"10.1136\/jitc-2022-005930","volume":"10","author":"V Glutsch","year":"2022","unstructured":"Glutsch V, Schummer P, Kneitz H, Gesierich A, Goebeler M, Klein D, et al. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG. J Immunother Cancer. 2022;10(11):e005930.","journal-title":"J Immunother Cancer"},{"issue":"10357","key":"858_CR110","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","volume":"400","author":"S Kim","year":"2022","unstructured":"Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022;400(10357):1008\u201319.","journal-title":"Lancet"},{"issue":"9","key":"858_CR111","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jdcr.2019.06.034","volume":"5","author":"BC Westbrook","year":"2019","unstructured":"Westbrook BC, Norwood TG, Terry NLJ, McKee SB, Conry RM. Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients. JAAD Case Rep. 2019;5(9):782\u20136.","journal-title":"JAAD Case Rep."},{"issue":"8","key":"858_CR112","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/annonc\/mdz187","volume":"30","author":"R Knackstedt","year":"2019","unstructured":"Knackstedt R, Sussman TA, McCahon L, Song JM, Funchain P, Gastman B. Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1\/PD-L1 axis inhibitors and TVEC: a report of two cases. Ann Oncol. 2019;30(8):1399\u2013400.","journal-title":"Ann Oncol"},{"key":"858_CR113","doi-asserted-by":"publisher","first-page":"S903","DOI":"10.1016\/j.annonc.2021.08.1478","volume":"32","author":"F Aroldi","year":"2021","unstructured":"Aroldi F, Middleton MR, Sacco JJ, Milhem MM, Curti BD, VanderWalde AM, et al. 1093TiP An open-label, multicenter, phase I\/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]. Ann Oncol. 2021;32:S903\u20134.","journal-title":"Ann Oncol"},{"issue":"1","key":"858_CR114","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1158\/2326-6066.CIR-13-0087","volume":"2","author":"AG Chapuis","year":"2014","unstructured":"Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, et al. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res. 2014;2(1):27\u201336.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"858_CR115","doi-asserted-by":"publisher","first-page":"e000450","DOI":"10.1136\/jitc-2019-000450","volume":"8","author":"KP Fabian","year":"2020","unstructured":"Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. 2020;8(1):e000450.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"858_CR116","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12149-012-0578-3","volume":"26","author":"A Salavati","year":"2012","unstructured":"Salavati A, Prasad V, Schneider CP, Herbst R, Baum RP. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. Ann Nucl Med. 2012;26(4):365\u20139.","journal-title":"Ann Nucl Med"},{"issue":"6","key":"858_CR117","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00432-020-03181-2","volume":"146","author":"J Zhang","year":"2020","unstructured":"Zhang J, Song Q, Cai L, Xie Y, Chen Y. The efficacy of (177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2020;146(6):1533\u201343.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"858_CR118","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/bjd.19150","volume":"184","author":"T Akaike","year":"2021","unstructured":"Akaike T, Qazi J, Anderson A, Behnia FS, Shinohara MM, Akaike G, et al. High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma. Br J Dermatol. 2021;184(2):319\u201327.","journal-title":"Br J Dermatol"},{"issue":"3","key":"858_CR119","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2967\/jnumed.121.262344","volume":"63","author":"J Ferdinandus","year":"2022","unstructured":"Ferdinandus J, Fendler WP, Lueckerath K, Berliner C, Kurzidem S, Hadaschik E, et al. Response to combined peptide receptor radionuclide therapy and checkpoint immunotherapy with ipilimumab plus nivolumab in metastatic Merkel cell carcinoma. J Nucl Med. 2022;63(3):396\u20138.","journal-title":"J Nucl Med"},{"issue":"22","key":"858_CR120","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1200\/JCO.20.00201","volume":"38","author":"SL Topalian","year":"2020","unstructured":"Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbe C, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial. J Clin Oncol. 2020;38(22):2476\u201387.","journal-title":"J Clin Oncol"},{"issue":"10404","key":"858_CR121","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0140-6736(23)00769-9","volume":"402","author":"JC Becker","year":"2023","unstructured":"Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, et al. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. Lancet. 2023;402(10404):798\u2013808.","journal-title":"Lancet"},{"issue":"4","key":"858_CR122","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-20-1301","volume":"11","author":"A Spreafico","year":"2021","unstructured":"Spreafico A, Hansen AR, Abdul Razak AR, Bedard PL, Siu LL. The future of clinical trial design in oncology. Cancer Discov. 2021;11(4):822\u201337.","journal-title":"Cancer Discov"},{"key":"858_CR123","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ejca.2010.11.002","volume":"47","author":"BA Reichgelt","year":"2011","unstructured":"Reichgelt BA, Visser O. Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993-2007. Eur J Cancer. 2011;47:579\u201385.","journal-title":"Eur J Cancer"},{"key":"858_CR124","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.canep.2016.09.001","volume":"45","author":"J Rubio-Casadevall","year":"2016","unstructured":"Rubio-Casadevall J, Hernandez-Pujol AM, Ferreira-Santos MC, et al. Trends in incidence and survival analysis in non-melanoma skin cancer from 1994 to 2012 in Girona, Spain: A population-based study. Cancer Epidemiol. 2016;45:6\u201310.","journal-title":"Cancer Epidemiol"},{"key":"858_CR125","first-page":"977","volume":"8","author":"SE Uitentuis","year":"2016","unstructured":"Uitentuis SE, Louwman MWJ, van Akkooi ACJ, Bekkenk MW. Treatment and survival of Merkel cell carcinoma since 1993: A population-based cohort study in The Netherlands. J Am Acad Dermatol. 2019;81:977\u201383.","journal-title":"J Am Acad Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00858-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00858-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00858-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T10:11:28Z","timestamp":1719051088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00858-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["858"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00858-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"21 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. Funding was provided by BMBF - DKTK (ED03).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JCB is receiving speaker\u2019s bureau honoraria from Amgen, Pfizer, and Sanofi and is a paid consultant\/advisory board member\/data and safety monitoring board (DSMB) member for Almirall, Boehringer Ingelheim, ICON, Merck, Pfizer, and Sanofi. His group receives research grants from Merck, HTG, IQVIA, and Alcedis. SU declares research support from Bristol Myers Squibb and Merck; speaker and advisory board honoraria from Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, and Novartis; and meeting and travel support from Almirall, Bristol-Myers Squibb, IGEA Clinical Biophysics, Merck Sharp & Dohme, Novartis, Pierre Fabre, and Sun Pharma. AS and DS declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent for publication"}},{"value":"No datasets were generated or analyzed for this review article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors were involved in the literature research, writing the initial draft and the revision process. All authors read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}